Global Continuous Glucose Monitoring Device Market Set for Unprecedented Growth: Projected to Reach USD 16.8 Billion by 2033

The global continuous glucose monitoring device market is on the brink of remarkable growth, as highlighted by a recent analysis report from Future Market Insights. In 2023, the market achieved impressive sales totaling USD 5.5 billion. With a forecasted compound annual growth rate (CAGR) of 11.9% from 2023 to 2033, the market is expected to surge to an astounding valuation of USD 16.8 billion by 2033.

A significant driver of this growth is the increasing demand for the sensor component, which is projected to experience a CAGR of approximately 11.6% over the same period. The sensor segment is anticipated to emerge as the leading revenue generator within the CGM device market, driven by advancements in technology and the growing need for accurate and real-time glucose monitoring.

Transform Your Business Trajectory with Data-Backed Insights from Our Continuous Glucose Monitoring Device Market Sample Report

Continuous glucose monitoring devices represent a groundbreaking innovation in diabetes management, revolutionizing how individuals tackle the challenges of this chronic condition. These advanced medical technologies provide real-time and continuous monitoring of glucose levels in the bloodstream, offering a level of accuracy and insight that surpasses traditional finger stick measurements.

The technology has proven invaluable for individuals living with diabetes, empowering them to make informed decisions about their lifestyle, diet, exercise regimen, and insulin dosing. By offering a comprehensive understanding of glucose fluctuations, CGM devices enable timely interventions that can significantly enhance the quality of life for those managing diabetes.

The projected growth and innovation within the global continuous glucose monitoring device market underscore its significance in the healthcare landscape. As technology continues to evolve, the potential for further advancements in diabetes management holds promise for millions worldwide.

Key features and benefits of CGM devices include:

  • Continuous Monitoring: CGM devices provide real-time glucose readings at regular intervals (usually every few minutes) throughout the day and night, enabling users to track their glucose levels without the need for frequent fingerstick testing.
  • Data Trends: CGM devices offer insights into glucose trends, helping users understand how their glucose levels change in response to various factors such as meals, physical activity, and medication.
  • Alerts and Alarms: CGM devices can be programmed to provide alerts and alarms when glucose levels are too high (hyperglycemia) or too low (hypoglycemia), helping users take timely corrective actions to avoid severe complications.
  • Data Sharing: Many CGM devices allow users to share their glucose data with healthcare professionals, caregivers, or family members, enabling remote monitoring and intervention when necessary.
  • Improved Diabetes Management: By having a better understanding of their glucose patterns, users can make informed decisions about insulin dosing, dietary choices, and physical activity to maintain optimal glucose control.

The CGM device market has seen significant growth in recent years due to the increasing prevalence of diabetes, technological advancements, and the growing demand for better diabetes management solutions. The market includes several well-established companies as well as newer entrants, each offering various features, accuracy levels, and form factors to cater to the diverse needs of individuals with diabetes.

Unleash Strategic Potential Get the Complete Report Here

Key Companies Profiled:

  • A. Menarini Diagnostics
  • Echo Therapeutics, Inc.
  • Abbott Laboratories
  • Bayer AG
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • GlySens Incorporated
  • Insulet Corporation
  • Johnson & Johnson
  • LifeScan
  • Medtronic plc
  • Medtrum Technologies, Inc.
  • Microchip Technology Inc.
  • Micron Technology Inc.
  • Nemaura Medical, Inc.

Segments Covered in Continuous Glucose Monitoring Device Industry Analysis:

By Component:

  • Transmitters
  • Sensors
  • Receivers

By End-Use:

  • Hospitals
  • Home Care
  • Other End-uses

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Cell and Gene Therapy Manufacturing Market Set for Remarkable Growth over USD 240 Billion in value by 2033

Future Market Insights (FMI) has released its latest forecast for the global cell and gene therapy manufacturing market, and the outlook is exceptionally promising. According to the report, the global market is expected to experience a staggering Compound Annual Growth Rate (CAGR) of 29% from 2023 to 2033. This robust growth projection highlights the market’s dynamic expansion, which saw significant progress in 2023, reaching an estimated USD 19.3 billion and is set to soar to approximately USD 240 billion by 2033.

The comprehensive research conducted by FMI reveals a remarkable upward trajectory for the cell and gene therapy manufacturing sector. Between 2018 and 2022, the market demonstrated a solid CAGR of around 22%, reflecting a period of substantial growth that has paved the way for the anticipated exponential increase over the next decade.

Unlock the Door to Innovation and Prosperity By Our Exclusive Sample Report

Among the key findings, the cell therapy manufacturing market size is expected to be the highest revenue-generating segment, with an impressive anticipated CAGR of 31.8% from 2023 to 2033. This surge in revenue is attributed to the rising incidence of cancer and other target diseases. Additionally, the increased focus on research and development spending in pharmaceutical companies is contributing significantly to the expansion of the market.

“The remarkable growth projections for the global cell and gene therapy manufacturing industry highlight the transformative impact of advanced medical technologies,” said Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.). “Our commitment to pioneering innovations and staying at the forefront of this dynamic industry positions us to contribute to and benefit from this unprecedented growth.”

The industry’s growth is further substantiated by the increasing adoption of cell and gene therapies for treating a spectrum of diseases, propelling the demand for advanced manufacturing technologies. As the market evolves, it presents exciting opportunities for companies to collaborate, innovate, and advance the development of life-changing therapies.

Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatments that are excessively utilized to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth. In addition to that, it has been estimated that more than 50 million people will be diagnosed with cancer within the next five years.

Report Highlights:

Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.

Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.

GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.

Competitive Landscape:

The surging interest of key public and private investors in the development of advanced therapies are expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.

Gain Essential Insights Get the Complete Report

Key Companies Profiled:

  • Thermo Fisher Scientific
  • Merck KGaA
  • Lonza
  • Catalent Inc.
  • Takara Bio Inc.
  • F. Hoffmann-La Roche Ltd
  • Wuxi Advanced Therapies
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novartis AG
  • Hitachi Chemical Co., Ltd.
  • Cellular Therapeutics
  • Miltenyi Biotec
  • Bluebird Bio Inc.

Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis:

By Therapy Type:

  • Cell Therapy Manufacturing
    • Stem Cell Therapy
    • Non-Stem Cell Therapy
  • Gene Therapy Manufacturing

By Scale:

  • Pre-commercial/ R&D Manufacturing
  • Commercial Scale Manufacturing

By Mode:

  • Contract Manufacturing
  • In-house Manufacturing

By Workflow:

  • Cell Processing
  • Cell Banking
  • Process Development
  • Fill & Finish Operations
  • Analytical And Quality Testing
  • Raw Material Testing
  • Vector Production
  • Other Workflows

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Aquaculture Vaccines Market Set to Surge with Projected Growth to USD 913.6 Million by 2033

The global aquaculture vaccines market is on the brink of significant expansion, with current valuations standing at USD 406 million. The market is projected to experience remarkable growth, reaching USD 913.6 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.5% from 2023 to 2033. This impressive growth trajectory highlights the increasing momentum within the aquaculture sector.

Aquaculture, which encompasses the farming of aquatic organisms such as fish, shellfish, and plants, has seen substantial advancements in recent years. This growth is driven by a rising consumer preference for seafood products, including canned fish and other aquaculture-related items. The surge in demand is largely attributed to the recognized nutritional benefits of seafood, which plays a crucial role in promoting human health.

Ignite Your Growth: Unveil the Future Opportunities in the Aquaculture Vaccines Market – Get Your Sample Report

“The exponential growth of the global aquaculture vaccines market signifies a paradigm shift in the industry landscape,” remarked FMI. “As consumers increasingly prioritize healthy and sustainable food options, the aquaculture sector emerges as a critical contributor to meeting these demands. The adoption of vaccines in aquaculture underscores a commitment to ensuring the well-being of aquatic organisms while maintaining environmental sustainability.”

Key Takeaways from Aquaculture Vaccines Market:

  • Europe holds more than 20% of the market share. This could be attributed to Norway being the largest exporter of salmon along with growing concerns regarding antimicrobial activities. The Norwegian Medicines Agency does make provision of specific guidelines and regulations related to the applications of autogenous vaccines. The European Commission has funded a huge-scale collaborative project under 7th Framework Programme for extending support to aquaculture industry.
  • North America holds a significant market share with the US witnessing a rising demand for safe and clean fish and other marine foodstuff.
  • The Asia-Pacific is expected to witness a sizable growth in aquaculture vaccines market going forward due to booming aquaculture vertical, thereby resulting in increase in production of various aquatic species like tilapia (especially in Japan).

Competitive Vaccines:

  • Virbac, in September 2020, did announce acquiring a series of tilapia vaccines from Ictyogroup (an animal health company specializing in research pertaining to biology). These two companies also inked a partnership agreement for Aqua Virbac division developing novel formulations and vaccines.
  • Barramundi Asia, in January 2020, did announce merging with Allergo Aqua with the objective of bringing fingerling research in-house. The method has thus helped in maintenance of long-term relationships.
  • Merck, in August 2020, completed acquisition of IdentiGEN to extend its line-up of livestock and aquaculture products.
  • Elanco, in December 2020, did move its headquarters to Indiana to complement its IPP (Innovation, Portfolio & Productivity) strategy and also establish a center of excellence for consolidation of future footprint.
  • CIBA, in April 2021, did launch Nodavac-R, which comes across as an injectable recombinant viral nervous necrosis (VNN) vaccine to avert vertical transmission in the brooders.
  • MSD Animal Health, in November 2019, did launch AQUAVAC Strep Sa-Si injectable and dip immersion vaccine against Streptococcis in the tilapia fish in LATAM.

Enhance Your Business Outcomes with the Strategic Insights from A Comprehensive Full Report

Key Companies Profiled:

  • GlaxoSmithKline plc
  • Merck & Co., Inc
  • Pfizer, Inc.
  • Sanofi SA
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Panacea Biotec, Ltd.
  • Biological E Limited
  • Bharat Biotech Ltd.
  • Novavax, Inc.

Market Segments Covered in Aquaculture Vaccines Industry Analysis:

Product Type Outlook:

  • Attenuated Live Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • DNA Vaccines
  • Recombinant Vaccines

Route of Administration:

  • Oral
  • Injected
  • Immersion & Spray

Regional Outlook:

  • Bacterial
  • Viral
  • Parasitic

Regional:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)


About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Encephalitis Treatment Market Poised for Remarkable Growth, Reaching USD 34.08 Billion by 2033

The global encephalitis treatment market is witnessing a robust expansion, with significant advancements anticipated in the coming years. As per the latest market research, the market, valued at USD 20.14 billion in 2023, is set to experience a Compound Annual Growth Rate (CAGR) of 5.4%. This growth trajectory is expected to drive the market to an estimated USD 34.08 billion by 2033.

Several key factors are propelling this growth. Technological advancements in healthcare are at the forefront, providing innovative solutions and enhancing treatment efficacy. Additionally, the rising prevalence of encephalitis is prompting increased demand for effective treatment options. Government and healthcare initiatives focused on improving diagnosis and treatment are also contributing to the market’s expansion.

Curious about the Effects of Recent Acquisitions in the Encephalitis Treatment Market Our Sample Report Now

Encephalitis, characterized by inflammation of the active tissues of the brain, poses significant challenges to healthcare providers worldwide. However, advancements in medical science have paved the way for effective treatment modalities aimed at minimizing brain swelling and preventing associated complications.

Treatment strategies vary depending on the underlying cause of encephalitis. In cases where bacterial infection is identified as the culprit, intravenous antibiotics are employed for effective management. Similarly, herpes-related encephalitis is treated with intravenous antiviral medication, primarily acyclovir. Additionally, supportive measures such as fever reduction, hydration, seizure management, and alleviation of intracranial pressure play crucial roles in the comprehensive treatment approach.

The forecasted growth of the global encephalitis treatment market underscores the collective efforts of the healthcare industry in addressing this debilitating condition. With a commitment to innovation and patient-centric care, stakeholders are poised to make significant strides in enhancing treatment outcomes and improving the quality of life for individuals affected by encephalitis.

Key Takeaways:

  • A dearth of trained professionals, high treatment costs, and poor healthcare infrastructure, especially in low-income countries, may impede the growth of the encephalitis treatment market.
  • The encephalitis treatment market in the US will expand at a CAGR of 5.2% during the assessment period.
  • Europe will emerge as an attractive pocket for the encephalitis treatment market due to increasing investment in the healthcare sector with the U.K recording a CAGR of 5.1% during the observation period.
  • By end-users, the hospital segment will generate the highest revenue and account for 50.5% of the market share in 2023.

Competitive Landscape:

  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Melinta Therapeutics LLC
  • Basilea Pharmaceutica Ltd.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi

Empower Your Business Decisions with the Insights from A Full Report Overview

More Insights into Encephalitis Treatment Market: 

In its latest report, FMI offers an unbiased analysis of the global encephalitis treatment market, providing historical data from 2018 to 2022 and forecast statistics for 202 to 20. For a comprehensive understanding of the global market potential, growth, and scope, the market is segmented on the basis of treatment, end-users, and region.

According to the same reports, based on segmentation, the hospital end-user segment will prove to be immensely remunerative during this period owing to the growing adoption of advanced technology in hospital settings. Based on region, the Asia Pacific will emerge as an opportunistic market for encephalitis treatment. The target market in this region will grow at a CAGR of 5.1% due to a high prevalence of Japanese encephalitis across Asia Pacific. In terms of countries, the US, India, China, and Korea will also contribute significantly to the growth of the encephalitis treatment market during the forecast period.

Key Segments Covered in the Encephalitis Treatment Industry Survey:

Encephalitis Treatment Market by Treatment:

  • Antiviral Agents
  • Steroid Injection
  • Antibiotics
  • Immunoglobulin Therapy
  • Plasmapheresis
  • Others

Encephalitis Treatment Market by End-Users:

  • Clinic
  • Hospitals
  • Others

Encephalitis Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Complicated Urinary Tract Infections Treatment Market Set for Robust Growth, Projected to Reach USD 16.1 Billion by 2033

The global complicated urinary tract infections treatment market is on a trajectory for significant growth, according to recent market projections. Valued at over USD 9.2 billion in 2023, the market is expected to surge to USD 16.1 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.76% over the forecast period.

The surge in the cUTI treatment market is driven by the increasing prevalence of cUTIs, fueled by the rise of drug-resistant bacteria and the overutilization of antibiotics. As these challenges escalate, the demand for effective treatment options is growing, contributing to the market’s expansion.

Healthcare professionals are increasingly turning to quinolones and cephalosporins as primary and secondary treatment options for managing complex UTI cases. This shift is a key factor driving the market’s growth, highlighting the critical role these antibiotics play in addressing severe infections and combating resistance.

Get Sample Copy of Latest Reports Complicated Urinary Tract Infections Treatment Market

Despite the optimistic outlook, the market faces challenges stemming from conflicting guidelines issued by various healthcare organizations regarding the management of cUTIs. These inconsistencies contribute to confusion among healthcare providers, thereby potentially impeding the growth trajectory of the cUTI treatment market.

“The projected growth of the global Complicated Urinary Tract Infections treatment market underscores the pressing need for effective strategies to combat the rising incidence of drug-resistant bacteria and streamline treatment protocols,” remarked FMI.

As stakeholders navigate through evolving guidelines and embrace innovative treatment modalities, collaboration among industry players and healthcare organizations will be pivotal in addressing the complexities associated with cUTIs and ensuring optimal patient outcomes.

Key Takeaways:

  • North America is projected to lead the market of complicated urinary tract infections with an estimated market value of USD 5.29 billion by end of the forecast period.
  • The market in East-Asia is expected to witness fastest CAGR of 5.1% while possessing 20% market share by end of 2033.
  • By drug class, Penicillin and combinations is expected witness fastest segment growth of 7.9% during the forecast period.
  • Quinolones segment is expected to possess hegemony with 48.6% market share by end of the forecast period.
  • By distribution channel, hospital pharmacies is anticipated to dominate market with 51% market share by 2033.

Competitive Landscape:

The global Complicated Urinary Tract Infections treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are:

  • Spero Therapeutics
  • Wockhardt
  • Venatorx Pharmaceuticals
  • Allecra Therapeutics
  • Nabriva Therapeutics AG
  • MerLion Pharmaceuticals
  • Allergan
  • Bayer AG
  • Pfizer, Inc
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC

Revolutionize Your Business Strategy with the Insights from Full Report Revealed

Some Recent Developments In This Industry Are:

  • In November 2020, Allergan announced FDA acceptance of Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
  • In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
  • In September 2021, BDR Pharma, one of India’s leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

Key Segments Profiled in the Complicated Urinary Tract Infections treatment Industry survey:

Complicated Urinary Tract Infections treatment market by Drug class:

  • Penicillin and combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitro furans

Complicated Urinary Tract Infections treatment market by Distribution channel:

  • Hospital Pharmacies
  • Gynecology and Urology Clinics
  • Drug stores
  • Retail Pharmacies

Complicated Urinary Tract Infections treatment market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Generalized Myasthenia Gravis Management Market Set for Remarkable Growth, Projected to Reach USD 2.96 Billion by 2033

The global generalized myasthenia gravis (GMG) managements market is on a strong growth trajectory, according to Future Market Insights. The market, valued at USD 1.32 billion in 2023, is expected to achieve an impressive compound annual growth rate (CAGR) of 7.6% from 2023 to 2033, reaching an estimated USD 2.96 billion by the end of the forecast period.

Generalized myasthenia gravis, a rare autoimmune disorder, leads to severe muscle fatigue and weakness. This condition arises from antibodies that interfere with the crucial interaction between muscles and nerves, causing debilitating symptoms. As the global population ages, the prevalence of GMG has been steadily rising, contributing to increased demand for effective management solutions.

Grab Your Exclusive Sample Report: Unveiling the Spectacular Growth of the Generalized Myasthenia Gravis (GMG) Management Market

Recent statistics from the National Library of Medicine indicate that in the USA alone, the incidence of generalized myasthenia gravis (GMG) is 20 per 100,000 people. Notably, there is a higher prevalence among females under 40 years old, while males over 50 years old exhibit a greater propensity. Additionally, childhood MG is more prevalent in Asian nations compared to Western populations, affecting roughly 50% of patients under the age of 15. Reports suggest that the prevalence of this disorder has been on the rise in recent decades, possibly attributed to improved healthcare data collection and the global trend of increasing disease prevalence.

Recognizing the importance of raising awareness and supporting those affected by GMG, numerous organizations, authorities, and sectors are actively engaged in advocacy efforts. The Myasthenia Gravis Foundation of America (MGFA), for instance, is leading initiatives to designate June as Myasthenia Gravis Awareness Month. Through comprehensive publicity campaigns and educational outreach, including the dissemination of a 23-page toolkit, the foundation aims to increase awareness about the condition and available treatment options. Consequently, there has been a notable expansion in the patient population seeking treatment for this ailment.

As the global GMG management market continues to evolve, fueled by advancements in medical research and increasing awareness initiatives, stakeholders across various sectors are poised to play a pivotal role in supporting individuals living with this rare autoimmune disorder.

Key Takeaways:

  • On the global level, the disease’s incidence has risen substantially over recent years. This surge is attributed to increased disease awareness and diagnosis rates in both developed and developing nations. The nation’s massively improved reimbursement guidelines concerning the disorder are cruising sales growth.
  • On the basis of the study conducted by the National Organization for Rare Disorders (NORD), the condition’s prevalence in the United Kingdom is estimated to be 15 per 100,000 people, a figure that has risen over time. The popularity of novel therapeutic approaches is growing in tandem with the escalating diagnosis speed and favorable reimbursement guidelines for the ailment.
  • This is expected to surge the attempts of the industry’s prominent stakeholders in order to establish and obtain approval for novel drugs to treat the illness. The age structure of the population is expected to be another vital factor driving market growth.
  • The proportion of people aged 80 and up in the EU population is predicted to more than double between 2021 and 2100, soaring from 6.0% to 14.6%. On the basis of the MDPI Journal of Clinical Medicine, the prevalence of the ailment surges progressively with age. The 60-89-year-old age group has the greatest incidence. As a result, the disease’s prevalence is increasing as the population’s average lifespan rises.
  • On the basis of the 2020 epidemiology of myasthenia gravis article posted by Value in Health Journal, the older population comprises of higher incidence of the ailment than younger ages. Furthermore, in the United Kingdom, the pervasiveness of the disorder in the aging population was 46.4 per 100,000, in comparison to 12 per 100,000 in young adulthood.

Competitive Landscape:

Key players in the global generalized myasthenia gravis (GMG) management market are strengthening the portfolio, pipeline, and treatment emphasis on unique disease treatments.

More Insights into the Generalized Myasthenia Gravis (GMG) Management Market:

The North American market is anticipated to dominate the global GMG management market. In 2020, the North American market was valued at worth USD 0.58 billion. The soaring incidence of the illness and the region’s aging population are the contributing factors to market growth during the forecast period. Furthermore, the region’s established healthcare facilities and favorable reimbursement policies are striving to improve diagnosis and therapy rates in both emerging and advanced economies.

Elevate Your Strategy with Full Report Access – Get It Now

Key Companies Profiled:

  • Alexion Pharmaceuticals,
  • Argenx,
  • UCB Biopharma,
  • Horizon Therapeutics,
  • Halozyme Therapeutics,
  • Hoffmann-La Roche AG,
  • Janssen Research & Development, LLC,
  • Immunovant Sciences GmbH,
  • Sanofi,
  • Cartesian Therapeutics

Key Segments Profiled in the Generalized Myasthenia Gravis (GMG) Management Industry Survey:

By Drug Types:

  • Monoclonal Antibodies
  • FcRn Inhibitors
  • Corticosteroid
  • Cholinesterase Inhibitors
  • Pharmacotherapy
  • Therapeutic Plasma Exchange

By End Users:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Frontotemporal Dementia Management Market Set for Significant Growth, Reaching USD 17.91 Million by 2033

The global frontotemporal dementia management market is on the brink of notable expansion, according to a recent analysis by Future Market Insights (FMI). The study highlights an anticipated market value of USD 10 million in 2023, with projections indicating a robust Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033. By the end of the forecast period, the market is expected to achieve a valuation of USD 17.91 million.

Frontotemporal dementia, a neurodegenerative disorder that predominantly affects individuals aged 65 years and older, is emerging as a significant healthcare challenge globally. This condition, alongside Alzheimer’s and other forms of dementia, presents considerable obstacles to effective management and care.

The rising prevalence of FTD underscores the urgency of addressing this condition. To support this endeavor, numerous non-profit organizations are actively contributing to research and development in this field. Notable entities such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc., are at the forefront of funding initiatives aimed at advancing FTD research and improving treatment options.

Gain Valuable Insights into the Rising Investments and Market Growth of Frontotemporal Dementia Management Market – Our Sample Report Now

These organizations play a pivotal role in advancing clinical trials and preclinical studies focused on developing innovative therapeutics to mitigate the progression of frontotemporal dementia. By supporting research into interventions that could potentially slow or halt the onset of dementia, they significantly contribute to the advancement of medical science in this field.

The market for frontotemporal dementia management has demonstrated promising growth, with a CAGR of 4% during the historical period from 2018 to 2022. However, with increasing awareness, research funding, and technological advancements, the market is expected to witness accelerated growth in the coming years.

The findings of this study underscore the pressing need for continued investment in research and development efforts aimed at combating frontotemporal dementia and related neurodegenerative disorders. By fostering collaboration between researchers, clinicians, and non-profit organizations, we can strive towards more effective treatments and improved outcomes for individuals affected by these debilitating conditions.

Key Takeaways from the Market Study:

  • From 2018 to 2022, the Frontotemporal Dementia Management market grew at a CAGR of 4%.
  • The global Frontotemporal Dementia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
  • As of 2033, the Frontotemporal Dementia Management Market is expected to reach USD 17.91 Million
  • According to the FMI analysis, hospitals account for the largest market share.
  • North America is expected to possess 25% market share for the Frontotemporal Dementia Management market.
  • The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Frontotemporal Dementia Management.” says an FMI analyst

Get Ahead of Curve the Full Report Now

Market Competition:

Key players in the Frontotemporal Dementia Management market are

  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Mylan N.V.
  • Merck & Company, Inc.
  • AstraZeneca plc.
  • Allergen plc

Recent Development:

  • In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
  • Alzheimer’s Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.

Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey:

Drug Class Type:

  • Antidepressants
    • Fluoxetine
    • Fluvoxamine
    • Sertraline
    • Paroxetine
    • Citalopram
    • Bupropion
    • Mirtazapine
  • Antipsychotics
    • Olanzapine
    • Quetiapine
    • Ziprasidone
    • Aripiprazole
    • Risperidone
    • Paliperidone

End-Users:

  • Hospitals
  • Specialty clinics
  • Others

Distribution Channel:

  • Hospital Pharmacy
  • Drug store
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Tuberculous Meningitis Treatment Market Set to Experience Robust Growth, Reaching USD 300 Billion by 2033

Future Market Insights (FMI) has released a groundbreaking study highlighting the substantial growth potential of the global tuberculous meningitis treatment market. According to the report, the market is projected to grow at a remarkable Compound Annual Growth Rate (CAGR) of 7.2% from 2023 to 2033, signaling significant opportunities for stakeholders and investors.

The market, valued at USD 150 billion in 2023, is anticipated to expand dramatically, with projections indicating it could potentially double to USD 300 billion by 2033. This exponential growth trajectory reflects the escalating demand for effective treatment solutions in combating tuberculous meningitis worldwide.

Get Access to Sample Now Tuberculous Meningitis Treatment Market

Tuberculous meningitis, a severe form of tuberculosis affecting the brain’s protective membranes, poses significant treatment challenges. The increasing prevalence and the urgent need for advanced therapeutic options are driving this rapid market expansion. The FMI report underscores a pivotal moment for healthcare providers, pharmaceutical companies, and investors to focus on innovative treatments and strategies to address this critical health issue.

The study highlights several key factors contributing to the market’s growth, including advances in medical research, heightened awareness of tuberculous meningitis, and increased investments in healthcare infrastructure globally. As the healthcare landscape evolves, there is a growing emphasis on developing and implementing effective treatment protocols to improve patient outcomes.

The FMI report serves as a crucial resource for industry professionals seeking to understand the dynamics of the tuberculous meningitis treatment market and identify emerging opportunities. The forecasted growth underscores the need for continued innovation and investment in treatment solutions to meet the rising demand.

Key Takeaways from the Market Study:

  • FMI projects the global tuberculous meningitis treatment market to expand at a 7.2% value CAGR by 2033
  • The global tuberculous meningitis treatment market is estimated at a market value of USD 150 Billion
  • The global tuberculous meningitis treatment market is expected to garner a market value of USD 300 Billion
  • Asia Pacific is forecast to be the most lucrative for tuberculous meningitis treatment market growth
  • North America is expected to grow at a CAGR of 6.9% in the assessment period 2023-2033.
  • Europe is expected to grow at a CAGR of 6.7% in the assessment period 2023-2033.
  • The adjunctive corticosteroid therapy segment is expected to hold the largest market share for tuberculous meningitis treatment in the forecast period 2023-2033.

“Tuberculous meningitis treatment market development may also be linked to reasons such as increased cross-country travel and an increase in the number of traffic accidents. A lot has been occurring in the vaccine R&D area as well, according to future clinical trial results.”Says an analyst at FMI

Market Competition:

Key players in the tuberculous meningitis treatment market are

  • Pfizer Inc.
  • GSK Inc.
  • Sanofi S.A
  • Novartis A.G
  • Merck & Co.
  • AstraZeneca Plc.
  • Biomed Pvt. Ltd
  • K.T.Z Company Limited
  • Sumitomo Group
  • Baxter International

Transform Your Business Access the Comprehensive Report Now

Recent Developments:

  • In January 2023, Baxter International Inc., a leading global medtech firm announced a comprehensive strategic plan to increase operational efficiencies, boost long-term performance, accelerate innovation, and create extra value for all stakeholders. These changes include the company’s plan to spin off its Renal Care and Acute Therapies global business units (GBUs) into a separate, publicly traded company; a simplified commercial and manufacturing footprint to improve underlying business performance; and additional portfolio actions to improve Baxter’s capital structure, including a review of strategic alternatives for the BioPharma Solutions (BPS) business.
  • In December 2022, Pfizer Inc. said that the FDA has accepted for consideration a Biologics License Application (BLA) for its experimental pentavalent meningococcal vaccination candidate (MenABCWY). MenABCWY was filed by Pfizer for the prevention of meningococcal illness caused by the most frequent serogroups in people aged 10 to 25.

Key Segments Profiled in the Tuberculous Meningitis Treatment Market Survey:

By Treatment:

  • Antibiotic Therapy
  • Adjunctive Corticosteroid Therapy
  • Neurosurgical Management

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Antimicrobial Glass Powder Market Set to Surge to USD 7,702.0 Million by 2034 with a Robust 10.6% CAGR

 

The global antimicrobial glass powder market value is anticipated to increase from USD 2,827.6 million in 2024 to USD 7,702.0 million by 2034. Over the assessment period, global demand for antimicrobial glass powder is projected to surge at a CAGR of 10.6%.

Bioactive-based antimicrobial glass powders are expected to remain in demand due to their widening usage in healthcare and other industries. The target segment will likely grow at a CAGR of 10.9% through 2034.

The antimicrobial glass powder industry is poised to grow rapidly during the next ten years. This can be attributed to factors like:

  • Expanding usage of antimicrobial glass powders across industries like healthcare, packaging, food & beverage, construction, personal care & cosmetics
  • Rising incidence of hospital-acquired infections
  • Increasing demand for sustainable antimicrobial materials to reduce disease spread
  • Growing emphasis on hygiene and infection control in diverse industries

Discover Growth Opportunities in Antimicrobial Glass Powder – Get Your Sample Report Now!

Antimicrobial glass powders are becoming highly sought-after products. This is due to their ability to prevent the growth of bacteria and other microorganisms. Growing adoption of these powders in industries like healthcare and food packaging for improving hygiene is expected to boost the market.

Antimicrobial glass powders are helping people address the growing global demand for enhanced infection-prevention technologies. Growing awareness of cleanliness standards and increasing infrastructure-building initiatives are set to foster market growth.

The rising popularity of nano-sized antimicrobial glass powders due to their multiple benefits is another key factor expected to boost the market. These powders are easily mixed into a variety of materials, such as coatings, polymers, and textiles, due to their small size.

Key Takeaways from the Report

  • The antimicrobial glass powder market is projected to thrive at 6% CAGR through 2034.
  • By type, the bioactive-based segment will likely account for a market share of 0% in 2024.
  • Based on size, the nano-sized segment is expected to account for a volume share of 9% in 2024.
  • East Asia is anticipated to hold a global market share of about 9% in 2034.
  • China’s market is estimated to be valued at US$ 1,512.6 million in 2034.
  • Demand in the United States will likely rise at 5% CAGR through 2034.

“The antimicrobial glass powder industry is predicted to expand around 2.7X through 2034 owing to growing demand from healthcare, food packing, and other sectors. This revolutionary material helps to increase product durability and infection control.” – says a lead analyst at Future Market Insights (FMI).

Who is Winning?

The antimicrobial glass powder market is fairly consolidated, with top players accounting for around 75% to 80% of the share. LG Electronics, Panasonic Industry Co. Ltd., Ishizuka Glass Co., Ltd., BioCote Limited, CD Bioparticles, Koshida Corporation, Vedayukt India Private Limited, Hongwu International Group Ltd, HeiQ Materials AG, Addmaster (UK) Limited, Corning Incorporated, SCHOTT AG, and American Elements are leading antimicrobial glass powder manufacturers and suppliers listed in the report.

Key companies are also using advanced manufacturing technologies and novel materials to develop antimicrobial glass powders with enhanced efficacy and durability. They also use strategies like partnerships, collaborations, alliances, facility expansions, acquisitions, and mergers to gain a competitive edge in the market.

Recent Development:

  • In February 2021, BioCote Limited launched a new venture called BioCote US to meet the rising demand for antimicrobial products in the United States.

Contact Our Sales Team Now to Discuss How You Can Acquire This Report and Gain Valuable Insights for Your Business.

Antimicrobial Glass Powder Market Segmentation

By Type:

  • Metal Oxide-based
  • Photocatalytic
  • Bioactive-based

By Size:

  • Nano-sized
  • Micro-sized

By Application:

  • Paints and Coating
  • Fiber
  • Plastics
  • Personal Care & Cosmetics
  • Commercial and Household Products
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia Pacific

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of ~400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Lithium Ion Battery Material Market Set for Explosive Growth: Projected Valuation of USD 371 Billion by 2034

 

The global lithium-ion battery material market is poised for substantial growth, with its valuation anticipated to reach USD 43.4 billion in 2024. This surge is driven by the growing demand for high-density batteries across various applications. The market is expected to experience a robust compound annual growth rate (CAGR) of 23.9% from 2024 to 2034, propelled by innovations and increased adoption in sectors such as electric vehicles and renewable energy storage. By 2034, the market is projected to soar to approximately USD 371.0 billion, highlighting a significant expansion driven by technological advancements and escalating demand for efficient and high-performance battery materials.

Ensuring the safety of lithium ion batteries is critical for market growth. Investments in developing safer battery chemistries and manufacturing processes contribute to consumer confidence and market adoption.

The proliferation of wearable electronics, such as smartwatches and fitness trackers, relies on compact and lightweight lithium ion batteries. The growing popularity of wearables contributes to the demand for battery materials.

Elevate your Business Strategy with Insights from our Industry Overview. Request a Sample to Uncover Growth Opportunities Now!

Advancements in artificial intelligence, Internet of Things, and smart grid technologies create new applications and requirements for energy storage, driving demand for lithium ion batteries and their materials.

The aerospace industry is exploring electrification for aircraft propulsion and auxiliary power units. Lithium ion batteries offer high energy density and lightweight characteristics suitable for aerospace applications, driving demand for battery materials.

The electrification trend extends to two wheeled vehicles such as motorcycles and bicycles. Electric bicycles and scooters are gaining popularity in urban areas as environmentally friendly and efficient modes of transportation, contributing to the demand for lithium ion batteries.

Research and development efforts focused on improving the performance and stability of anode and cathode materials, such as silicon anodes and high nickel cathodes, are driving innovation in the lithium ion battery material market.

Besides electric vehicles, stationary energy storage systems for residential, commercial, and utility scale applications are becoming increasingly important. The systems utilize lithium ion batteries to store excess renewable energy or provide backup power, driving demand for battery materials.

Key Takeaways from the Market Study

  • Global lithium ion battery material market was valued at US$ 34.2 billion in 2023.
  • From 2019 to 2023, the market demand expanded at a CAGR of 28.4%.
  • The market in Japan is expected to expand at a CAGR of 25.9% through 2034.
  • By type, the cathode material segment to account for a CAGR of 23.7% through 2034.
  • The market in Korea is expected to expand at a CAGR of 26.1% through 2034.
  • In terms of application, the automotive segment to account for a share of 23.5% in 2024.

“Collaboration among industry players, including battery manufacturers, material suppliers, and technology providers, accelerates innovation and market expansion by combining expertise and resources,” Says Analyst at Future Market Insights, Inc.

Get in Touch with Our Sales Experts Now to Learn How This Report Can Benefit Your Business.

Competitive Landscape

Prominent players in the lithium ion battery material market are Umicore, Targray, LG Chem, BTR New Energy, Shanshan Technology, Showa Denko K.K, Kureha Battery Materials, Mitsubishi Chemical, Asahi Kasei, and Sumitomo Corporation, among others.

Key Developments

  • In 2023, BASF collaborated with Nanotech Energy, marking a pivotal step towards the local production of lithium ion batteries in North America with a reduced carbon footprint and locally sourced recycled content.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global lithium ion battery material market, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.

To understand opportunities in the lithium ion battery material market, the market is segmented on the basis of type (cathode material, anode material, lithium ion battery separator, electrolyte), and application (automotive, grid energy storage, consumer electronics, others), across seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, and the Middle East & Africa).

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of ~400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube